Incyte stops PhIII trial for PI3K inhibitor after primary endpoint failure
Incyte has called it quits on a Phase III study for its oral PI3K inhibitor, parsaclisib, a year after withdrawing its accelerated approval pitch for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
